16 Healthcare Stocks Moving In Monday's Pre-Market Session

Gainers

• Medicines Co, Inc. (NASDAQ:MDCO) shares rose 10.6% to $38.74 during Monday's pre-market session. The market cap seems to be at $2.6 billion.
• DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) shares surged 7.4% to $0.82.
• Chiasma, Inc. (NASDAQ:CHMA) stock increased by 6.2% to $5.50. The most recent rating by Piper Jaffray, on July 31, is at Overweight, with a price target of $11.00.
• Aptevo Therapeutics, Inc. (NASDAQ:APVO) shares rose 5.0% to $0.78. The market cap seems to be at $39.9 million.
• Clearside Biomedical, Inc. (NASDAQ:CLSD) shares increased by 4.4% to $0.74.
• Bristol-Myers Squibb, Inc. (NYSE:BMY) shares rose 4.0% to $48.45. The market cap seems to be at $74.2 billion. According to the most recent rating by Atlantic Equities, on August 14, the current rating is at Overweight.
• HEXO, Inc. (NYSE:HEXO) shares moved upwards by 3.6% to $4.15. The market cap stands at $1.0 billion. According to the most recent rating by Oppenheimer, on June 25, the current rating is at Perform.
• Celgene, Inc. (NASDAQ:CELG) shares rose 3.3% to $97.10. The market cap stands at $65.8 billion.
• AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) stock rose 2.8% to $0.68. The market cap stands at $571.7 million.
• Genfit, Inc. (NASDAQ:GNFT) stock rose 2.6% to $17.12. The market value of their outstanding shares is at $638.7 million.
• Sangamo Therapeutics, Inc. (NASDAQ:SGMO) stock rose 2.1% to $11.25.
• Invitae, Inc. (NYSE:NVTA) stock moved upwards by 2.0% to $24.50.
• Canopy Growth, Inc. (NYSE:CGC) stock increased by 2.0% to $25.40. The most recent rating by Seaport Global, on August 26, is at Buy, with a price target of $31.00.

Losers

• Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) shares declined 2.9% to $111.99 during Monday's pre-market session. The market cap seems to be at $24.1 billion. According to the most recent rating by JP Morgan, on July 31, the current rating is at Overweight.
• Amgen, Inc. (NASDAQ:AMGN) stock fell 2.6% to $193.90. The market cap seems to be at $108.8 billion. The most recent rating by Mizuho, on August 19, is at Neutral, with a price target of $212.00.
• Viveve Medical, Inc. (NASDAQ:VIVE) shares declined 2.4% to $0.12. According to the most recent rating by Ladenburg Thalmann, on July 24, the current rating is at Neutral.